ArticleCureus2025
Mesenchymal Chondrosarcoma of the Mandible: A Diagnostic Dilemma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mendelian randomization analysis of causal relationships between chondrosarcoma and angiogenesis related genes.Discover oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal chondrosarcomas (MCs) are rare malignant mesenchymal neoplasms of the head and neck region. They originate either primarily from preexisting cartilage or secondarily from Paget's disease and fibrous dysplasia. In the head and neck region, the larynx, maxilla, and nasal cavity are the most common sites. Mandibular chondrosarcoma is quite rare. On CT scan, it appears as a lobulated mass containing a chondroid matrix. Adequate tissue sampling is essential for accurate histopathological and immunohistochemical diagnosis to avoid misdiagnosis with its mimickers. The prognosis of MC is considered poor due to its high tendency for recurrence, either locally or through hematogenous metastasis. The lungs are the most common site for metastasis. Therefore, extensive resection is associated with fewer recurrences and a better survival rate than limited resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.